The liberals demanding pharmaceutical price controls, and the Republicans warming to the idea, have moved on from their outrage over the Hepatitis C cure that debuted two years ago. Perhaps that’s because their fury was entirely synthetic—as even Democrats on the Senate Finance Committee now concede.

That’s not how Ron Wyden of Oregon and his Republican wingman Chuck Grassley of Iowa would characterize the findings of their 18-month investigation into Gilead Sciences and the drug Sovaldi. But after examining more than...